Enriching cancer pharmacology with drugs of marine origin

Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer

(2018) KOICHI SAKAGUCHI et al.   ANTICANCER RESEARCH

Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells

(2018) Carlos M. Galmarini et al.   BMC CANCER

Marine natural products

(2018) John W. Blunt et al.   NATURAL PRODUCT REPORTS

OUP accepted manuscript

(2018)   NEURO-ONCOLOGY

A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314)

(2018) Eric S. Schafer et al.   PEDIATRIC BLOOD & CANCER

Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition

(2018) Takaaki Oba et al.   Oncotarget

Antitumor Potential of Marine Natural Products: A Mechanistic Investigation

(2018) Liping Hu et al.   Anti-Cancer Agents in Medicinal Chemistry

Efficacy and safety of lurbinectedin (PM1183) in small cell lung cancer (SCLC): Results from a phase 2 study.

(2018) Jose Manuel Trigo Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group

(2018) Giovanni Grignani et al.   LANCET ONCOLOGY

Marine Natural Products in Medicinal Chemistry

(2018) Carlos Jiménez   ACS Medicinal Chemistry Letters

ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line

(2018) Anna F Farago et al.   Future Oncology

Lurbinectedin (PM01183), a selective inhibitor of active transcription, effectively eliminates both cancer cells and cancer stem cells in preclinical models of uterine cervical cancer

(2018) Eriko Yokoi et al.   INVESTIGATIONAL NEW DRUGS

First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors

(2018) Elena Elez et al.   INVESTIGATIONAL NEW DRUGS

Clogging the Ubiquitin-Proteasome Machinery with Marine Natural Products: Last Decade Update

(2018) Gerardo Della Sala et al.   Marine Drugs

The antitumor drugs trabectedin and lurbinectedin induce transcription-dependent replication stress and genome instability

(2018) Emanuela Tumini et al.   MOLECULAR CANCER RESEARCH

Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine

(2017) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option?

(2017) Luca Pompili et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates

(2017) David Newman et al.   Marine Drugs

The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

(2017) Simon D Harding et al.   NUCLEIC ACIDS RESEARCH

Efficacy of eribulin in breast cancer: a short report on the emerging new data

(2017) Gelareh Eslamian et al.   OncoTargets and Therapy

Plitidepsin: design, development, and potential place in therapy

(2017) Sara Alonso-Álvarez et al.   Drug Design Development and Therapy

Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models

(2017) Lucia Martinez-Cruzado et al.   NEOPLASIA

Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives

(2016) Erlinda M. Gordon et al.   ADVANCES IN THERAPY

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1

(2016) P. G. Richardson et al.   BLOOD

Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus

(2016) Matt L. Harlow et al.   CANCER RESEARCH

Multidrug-resistant cancer cells and cancer stem cells hijack cellular systems to circumvent systemic therapies, can natural products reverse this?

(2016) Qian Zhang et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results

(2016) S. J. Harrison et al.   CLINICAL CANCER RESEARCH

One size does not fit all: Challenging some dogmas and taboos in drug discovery

(2016) Christina LL Chai et al.   Future Medicinal Chemistry

Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma†

(2016) Akira Kawai et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: Report of two cases

(2016) Yannis Metaxas et al.   LUNG CANCER

Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells

(2016) G. Santamaria Nunez et al.   MOLECULAR CANCER THERAPEUTICS

Counting on natural products for drug design

(2016) Tiago Rodrigues et al.   Nature Chemistry

Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary

(2016) Ryoko Takahashi et al.   PLoS One

Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product Plitidepsin

(2016) Alejandro Losada et al.   Scientific Reports

Thiarabine, 1-(4-Thio-β-D-arabinofuranosyl)cytosine. A Deoxycytidine Analog With Excellent Anticancer Activity

(2015) W.B. Parker et al.   CURRENT MEDICINAL CHEMISTRY

Antibody-drug conjugates: Intellectual property considerations

(2015) Ulrich Storz   mAbs

Can Some Marine-Derived Fungal Metabolites Become Actual Anticancer Agents?

(2015) Nelson Gomes et al.   Marine Drugs

Up-regulation of eEF1A2 promotes proliferation and inhibits apoptosis in prostate cancer

(2014) Yue Sun et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors

(2014) Marta Martínez-Díez et al.   BIOCHEMICAL PHARMACOLOGY

Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

(2014) Kristi McIntyre et al.   BREAST CANCER RESEARCH AND TREATMENT

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states

(2014) T Yoshida et al.   BRITISH JOURNAL OF CANCER

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models

(2014) Yasuhiro Funahashi et al.   CANCER SCIENCE

Trabectedin and Plitidepsin: Drugs from the Sea that Strike the Tumor Microenvironment

(2014) Carlos Galmarini et al.   Marine Drugs

Access to and use of marine genetic resources: understanding the legal framework

(2014) Laura E. Lallier et al.   NATURAL PRODUCT REPORTS

New Interfacial Microtubule Inhibitors of Marine Origin, PM050489/PM060184, with Potent Antitumor Activity and a Distinct Mechanism

(2013) Benet Pera et al.   ACS Chemical Biology

From old alkylating agents to new minor groove binders

(2013) Stéphane Puyo et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Trabectedin mechanism of action: what’s new?

(2013) Maurizio D’Incalci   Future Oncology

Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma

(2013) V. Ribrag et al.   HAEMATOLOGICA

Comparison ofin vitroandin vivobiological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104)

(2013) Michela Romano et al.   INTERNATIONAL JOURNAL OF CANCER

Isolation and First Total Synthesis of PM050489 and PM060184, Two New Marine Anticancer Compounds

(2013) María Jesús Martín et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases

(2013) Lars Petter Jordheim et al.   NATURE REVIEWS DRUG DISCOVERY

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

(2012) Peter D Senter et al.   NATURE BIOTECHNOLOGY

Brentuximab vedotin

(2012) Anas Younes et al.   NATURE REVIEWS DRUG DISCOVERY

A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer

(2011) K. Aogi et al.   ANNALS OF ONCOLOGY

A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells

(2011) A. V. Singh et al.   BLOOD

XPF-Dependent DNA Breaks and RNA Polymerase II Arrest Induced by Antitumor DNA Interstrand Crosslinking-Mimetic Alkaloids

(2011) Sascha Feuerhahn et al.   CHEMISTRY & BIOLOGY

Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials

(2011) B. C. Potts et al.   CURRENT CANCER DRUG TARGETS

CD30-targeted antibody therapy

(2011) Anas Younes   CURRENT OPINION IN ONCOLOGY

A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: A gynecologic oncology group study

(2011) Bradley J. Monk et al.   GYNECOLOGIC ONCOLOGY

Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel

(2011) Michael Millward et al.   INVESTIGATIONAL NEW DRUGS

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes

(2011) Patrick Schöffski et al.   LANCET ONCOLOGY

Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells

(2011) D. G. Soares et al.   MOLECULAR CANCER THERAPEUTICS

PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity

(2010) JFM Leal et al.   BRITISH JOURNAL OF PHARMACOLOGY

Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma

(2010) M. V. Mateos et al.   CLINICAL CANCER RESEARCH

Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin(NPI-2358) in Patients with Solid Tumors or Lymphomas

(2010) M. M. Mita et al.   CLINICAL CANCER RESEARCH

Marine natural products as sources of novel scaffolds: achievement and concern

(2010) De-Xin Kong et al.   DRUG DISCOVERY TODAY

The pharmaceutical value of marine biodiversity for anti-cancer drug discovery

(2010) Patrick M. Erwin et al.   ECOLOGICAL ECONOMICS

eEF1A: Thinking Outside the Ribosome

(2010) Maria K. Mateyak et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine

(2010) Javier Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

A Review of Trabectedin (ET-743): A Unique Mechanism of Action

(2010) Maurizio D'Incalci et al.   MOLECULAR CANCER THERAPEUTICS

What lies underneath: Conserving the oceans' genetic resources

(2010) J. M. Arrieta et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies

(2009) Laurent Ducry et al.   BIOCONJUGATE CHEMISTRY

Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells

(2009) C. P. Miller et al.   BLOOD

Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma

(2009) D. Chauhan et al.   BLOOD

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

(2009) S. Goel et al.   CLINICAL CANCER RESEARCH

Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors

(2009) A. R. Tan et al.   CLINICAL CANCER RESEARCH

Natural products and drug discovery. Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia?

(2009) Hong-Fang Ji et al.   EMBO REPORTS

Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2009) Linda T. Vahdat et al.   JOURNAL OF CLINICAL ONCOLOGY

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors

(2009) C. Forni et al.   MOLECULAR CANCER THERAPEUTICS

Defined salt formulations for the growth of Salinispora tropica strain NPS21184 and the production of salinosporamide A (NPI-0052) and related analogs

(2008) Ginger Tsueng et al.   APPLIED MICROBIOLOGY AND BIOTECHNOLOGY

Population pharmacokinetics meta-analysis of plitidepsin (Aplidin®) in cancer subjects

(2008) Ricardo Nalda-Molina et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Xenohormesis: Sensing the Chemical Cues of Other Species

(2008) Konrad T. Howitz et al.   CELL

Von Hippel-Lindau-Coupled and Transcription-Coupled Nucleotide Excision Repair-Dependent Degradation of RNA Polymerase II in Response to Trabectedin

(2008) G. J. Aune et al.   CLINICAL CANCER RESEARCH

Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase

(2008) T. Okouneva et al.   MOLECULAR CANCER THERAPEUTICS